1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea is a complex chemical compound and **it's more commonly known as BCNU (or Carmustine)**.
**BCNU is an anti-cancer drug**. It's classified as a **nitrosourea alkylating agent**.
Here's why it's important for research:
* **Treatment of Cancers:** BCNU is used to treat various types of cancers, including:
* Brain tumors (such as glioblastoma multiforme)
* Multiple myeloma
* Hodgkin lymphoma
* Non-Hodgkin lymphoma
* Malignant melanoma
* **Mechanism of Action:** BCNU works by damaging the DNA of cancer cells, preventing them from multiplying and ultimately leading to their death.
* **Research Focus:** BCNU continues to be a subject of research for several reasons:
* **Understanding its effectiveness:** Scientists are studying the best ways to use BCNU in combination with other treatments to maximize its effectiveness and minimize side effects.
* **Developing new drugs:** BCNU's mechanism of action has inspired the development of other alkylating agents with potentially improved properties.
* **Overcoming drug resistance:** Research is ongoing to understand how cancer cells develop resistance to BCNU and to find ways to overcome this resistance.
* **Drug delivery:** Studies are investigating new ways to deliver BCNU to the tumor site more effectively, reducing damage to healthy tissues.
**It's important to note that BCNU is a powerful drug with serious side effects.** It's only used under the supervision of a qualified healthcare professional.
| ID Source | ID |
|---|---|
| PubMed CID | 55456 |
| CHEMBL ID | 2104789 |
| SCHEMBL ID | 27914 |
| MeSH ID | M0150238 |
| Synonym |
|---|
| urea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl] 1-nitroso |
| nsc-608678 |
| nsc608678 |
| tauromustine |
| tauricyt |
| tcnu |
| ls-2667 , |
| tauromustine [inn] |
| 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-n,n-dimethylethanesulfonamide |
| ethanesulfonamide, 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-n,n-dimethyl- |
| ccris 6346 |
| tauromustina [inn-spanish] |
| 1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea |
| 1-(2-chloroethyl)-3-(2-(dimethylsulfamoyl)ethyl)-1-nitrosourea |
| tauromustinum [inn-latin] |
| 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea |
| 85977-49-7 |
| unii-511f69k76y |
| tauromustinum |
| tauromustina |
| 511f69k76y , |
| CHEMBL2104789 |
| tauromustine [who-dd] |
| tauromustine [mart.] |
| SCHEMBL27914 |
| DTXSID20235317 |
| 2-(3-(2-chloroethyl)-3-nitrosoureido)-n,n-dimethylethane-1-sulfonamide |
| Q27260849 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In comparison with control cells that were transfected with the parent vector, the ATase-expressing clones were considerably more resistant to the toxic effects of the methylating agents N-methyl-N-nitrosourea and methylmethanesulphonate or the chloroethylating agents Mz or taurine chloroethylnitrosourea, but unchanged in their susceptibility to the bis-chloroethylating agent nitrogen mustard." | ( Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents. Dexter, TM; Jelinek, J; Kleibl, K; Margison, GP, 1988) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetic properties of tauromustine (TCNU) were studied in 31 cancer patients who participated in phase I trials." | ( Pharmacokinetics of tauromustine in cancer patients. Phase I studies. Ellman, M; Gunnarsson, PO; Hansen, HH; Macpherson, JS; Polacek, J; Smyth, JF; Vibe-Petersen, J; Warrington, PS, 1989) | 0.28 |
| "The pharmacokinetic profiles of 5-fluorouracil (5-FU) and tauromustine (TCNU) were investigated in NMRI mice following their administration either alone or as part of simultaneous or sequential combinations." | ( 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice. Bibby, MC; Hill, SR, 1994) | 0.29 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results show that the route of administration influences plasma concentrations, bioavailability and tissue and tumour concentrations." | ( Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations. Bibby, MC; Bloomer, JC; Double, JA; Loadman, PM, 1988) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " TCNU was given orally at a dosage of 130 mg/m2 every fifth week." | ( Phase II study of tauromustine in disseminated malignant melanoma. Bergh, J; Blomquist, E; Gjedde, SB; Lindegaard-Madsen, E; Mouridsen, HT; Nolte, H, 1989) | 0.28 |
| " The absolute levels of TCNU obtained with a dose of 100 mg TCNU/kg bodyweight were at most time points, three to four times those obtained with dosage of 25 mg TCNU/kg." | ( Experimental cerebral and plasma pharmacokinetic studies of TCNU: implications for brain tumour chemotherapy. Macpherson, JS; Miller, JD; Smyth, J; Whittle, IR, 1987) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 26 (47.27) | 18.7374 |
| 1990's | 29 (52.73) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (11.11%) | 5.53% |
| Reviews | 1 (1.59%) | 6.00% |
| Case Studies | 1 (1.59%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 54 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||